Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M9JJ
|
|||
| Former ID |
DIB004929
|
|||
| Drug Name |
DOV-216419
|
|||
| Synonyms |
Triple serotonin/dopamine/norepinephrine reuptake inhibitor (depression/pain), Dov; Triple serotonin/dopamine/norepinephrine reuptake inhibitor (depression/pain), Euthymics
Click to Show/Hide
|
|||
| Indication | Attention deficit hyperactivity disorder [ICD-11: 6A05.Z; ICD-9: 314] | Phase 3 | [1] | |
| Major depressive disorder [ICD-11: 6A70.3; ICD-10: F32.2] | Investigative | [2] | ||
| Company |
DOV Pharmaceutical Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H15N
|
|||
| Canonical SMILES |
C1C2C1(CNC2)C3=CC4=CC=CC=C4C=C3
|
|||
| InChI |
1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1
|
|||
| InChIKey |
HKHCSWPSUSWGLI-CABCVRRESA-N
|
|||
| CAS Number |
CAS 924012-43-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03605849) A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder. U.S. National Institutes of Health. | |||
| REF 2 | The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.